Founded in 2015 by Nobel Laureate Professor Barry J. Marshall, who was awarded the Nobel Prize for his groundbreaking discovery of Helicobacter pylori, Shenzhen Hongmed-Infagen Co., LTD. is a high-tech enterprise dedicated to revolutionising the diagnosis and treatment of gastrointestinal diseases. The company primarily focuses on conditions associated with Helicobacter pylori, developing personalised treatment strategies for multi-drug resistant strains. Concurrently, Hongmed-Infagen is advancing novel products for intestinal cancer screening and prevention, including diagnostics f...